These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 15234237)

  • 1. Recent advances in bladder cancer diagnostics.
    Sanchez-Carbayo M
    Clin Biochem; 2004 Jul; 37(7):562-71. PubMed ID: 15234237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and epigenetic aspects of bladder cancer.
    Kim WJ; Quan C
    J Cell Biochem; 2005 May; 95(1):24-33. PubMed ID: 15759278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
    Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
    Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
    Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma.
    Wang XS; Zhang Z; Wang HC; Cai JL; Xu QW; Li MQ; Chen YC; Qian XP; Lu TJ; Yu LZ; Zhang Y; Xin DQ; Na YQ; Chen WF
    Clin Cancer Res; 2006 Aug; 12(16):4851-8. PubMed ID: 16914571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
    Lotan Y; Roehrborn CG
    J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
    Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
    Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
    Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary bladder tumor markers.
    Lokeshwar VB; Selzer MG
    Urol Oncol; 2006; 24(6):528-37. PubMed ID: 17138134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers for detection, surveillance and prognostication of bladder cancer.
    Vrooman OP; Witjes JA
    Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of bladder cancer by analysis of urinary fibronectin.
    Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
    Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.